Therapeutics

Allogene, SpringWorks to Test Drug Combo in Multiple Myeloma Trial

6 days ago   |   By Xconomy

Springworks Therapeutics and Allogene Therapeutics have agreed to collaborate on a clinical trial to test a combination of an investigational cancer drug from each biotech in patients with multiple myeloma. The experimental treatment from Springworks, nirogacestat, is one of the four drug compounds that the company took off the Pfizer shelf when it spun out in 2017. Stamford, CT-based Springworks is studying nirogacestat in a Phase 3 trial enrolling patients with desmoid tumors, rare growths that form in the connective tissue and, while benign, can cause debilitation and disfigurement. The...
Read more ...

 


Search by Tags

   Therapeutics      Drugs      Tissue      Drug      Biotech      BioTech      Cancer      Clinical      National blog main      New York blog main      New York top stories      San Francisco      San Francisco blog main      San Francisco top stories      Allogene      Antibody-drug conjugate      BCMA      Cancer      Cancer immunotherapy      CAR-T      Clinical Trial      Collaboration      GlaxoSmithKline      Life Sciences      Multiple Myeloma      Oncology      Pfizer      SpringWorks Therapeutics  


World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

World Biotechnology Congress 2019

Hilaris Conferences is going to host its premier World Biotechnology Congress 2019 during October 01-02, 2019, Valencia, Spain. Biotechnology 2019 Congress aim to create a... Read more ...

2nd International Conference on Tissue Science and Regenerative Medicine

This conference is designed for experts in academia and industries working in the tissue science and regenerative field, this conference will examine cutting-edge research in... Read more ...

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Revolution Medicines Maps Out an IPO to Reach Cancer's Frontiers

Cancer research has revealed proteins known to play a role in the disease, but with no known way of stopping what they do. In pharmaceutical parlance, they're “undruggable.”... Read more ...

AveXis Inc.: Research Associate III

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Student Assistant

Mirati Therapeutics: Mirati Therapeutics is a targeted oncology company developing an advanced pipeline of breakthrough medicines for precisely defined patient populations San... Read more ...

Inhibition of lignification of Zizania latifolia with radio frequency...

Zizania latifolia is easily lignified after harvesting, leading to the degradation of food quality and commercial value. Thus, this study evaluated the effect of radio... Read more ...

Performance difference of graph-based and alignment-based hybrid error...

The error-prone third-generation sequencing long reads can be corrected by the high-quality second-generation sequencing short reads, which is referred to as hybrid error... Read more ...

CHROMATIX: computing the functional landscape of many-body chromatin...

Chromatin interactions are important for gene regulation and cellular specialization. Emerging evidence suggests many-body spatial interactions play important roles in... Read more ...

Bachem: Validation Engineer II, QA

Bachem: Your Responsibilities The Validation Engineer II fulfills a critical role in GMP operations. This individual must plan and execute validation studies, Vista, CA, US ... Read more ...

AveXis Inc.: Senior Scientist, Molecular Biology

AveXis Inc.: OverviewReady to join a team committed to developing and commercializing gene therapies for patients and families devastated by rare neurological gene San Diego... Read more ...

Mirati Therapeutics: Talent Partner

Mirati Therapeutics: Reporting to the Head of Business, Culture and Talent this role will be partner with C-Level executive(s) and their staff. This role will be responsib San... Read more ...

Selective inhibition of matrix metalloproteinase 10 with a single-domain...

Since their discovery, the matrix metalloproteinase family of proteases have been considered as therapeutic targets in numerous diseases and disorders. Unfortunately, clinical... Read more ...